Loading company
$14.83+6.5%Sep 29 close
- 1M
- +30.6%
- 6M
- +352.0%
- 1Y
- +194.7%
- 5Y
- -23.8%
$14.83+6.5%Sep 29 close
AbCellera Biologics Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $4.1M | $17.1M | -76.29% |
| Profit | -$55.4M | -$34.7M | -59.61% |
| Profit per share | -$0.18 | -$0.12 | -50.00% |
| Free Cash Flow | $23.8M | -$45.8M | +151.98% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Biologics Inc . AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from AbCellera Biologics Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
AbCellera Biologics Inc. has no earnings call transcript available.